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Abstract
Schizophrenia is highly heritable, yet its underlying pathophysiology remains largely unknown. Among the most well-replicated
ﬁndings in neurobiological studies of schizophrenia are deﬁcits in myelination and white matter integrity; however, direct
etiological genetic and cellular evidence has thus far been lacking. Here, we implement a family-based approach for genetic
discovery in schizophrenia combined with functional analysis using induced pluripotent stem cells (iPSCs). We observed
familial segregation of two rare missense mutations in Chondroitin Sulfate Proteoglycan 4 (CSPG4) (c.391G>A [p.A131T],
MAF 7.79× 10−5 and c.2702T>G [p.V901G], MAF 2.51× 10−3). The CSPG4A131T mutation was absent from the Swedish
Schizophrenia Exome Sequencing Study (2536 cases, 2543 controls), while the CSPG4V901G mutation was nominally enriched
in cases (11 cases vs. 3 controls, P= 0.026, OR 3.77, 95% CI 1.05–13.52). CSPG4/NG2 is a hallmark protein of
oligodendrocyte progenitor cells (OPCs). iPSC-derived OPCs from CSPG4A131T mutation carriers exhibited abnormal post-
translational processing (P= 0.029), subcellular localization of mutant NG2 (P= 0.007), as well as aberrant cellular morphology
(P= 3.0× 10−8), viability (P= 8.9× 10−7), and myelination potential (P= 0.038). Moreover, transfection of healthy non-
carrier sibling OPCs conﬁrmed a pathogenic effect on cell survival of both the CSPG4A131T (P= 0.006) and CSPG4V901G
(P= 3.4× 10−4) mutations. Finally, in vivo diffusion tensor imaging of CSPG4A131T mutation carriers demonstrated a reduction
of brain white matter integrity compared to unaffected sibling and matched general population controls (P= 2.2× 10−5).
Together, our ﬁndings provide a convergence of genetic and functional evidence to implicate OPC dysfunction as a candidate
pathophysiological mechanism of familial schizophrenia.
Introduction
Schizophrenia is a severely debilitating psychiatric dis-
order affecting ~1% of the population worldwide [1]. The
strongest known determinant for developing schizo-
phrenia is family history. A meta-analysis, which included
ﬁve decades of twin studies, concluded a heritability
estimate (h2) of 0.77 ± 0.05, with a relatively limited
contribution of shared environmental inﬂuences (c2)
(0.013 ± 0.025) [2].
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The Psychiatric Genomics Consortium recently reported a
genome-wide association study (GWAS) investigating
36,989 cases and 113,075 controls, in which 128 genome-
wide signiﬁcant single-nucleotide variants were identiﬁed
across 108 independent genomic loci, suggesting an impor-
tant contribution of common genetic variation to schizo-
phrenia risk [3]. However, a large proportion of the
heritability for schizophrenia remains unexplained, leaving
many genetic variants remaining to be discovered. Therefore,
increasing attention has also been focused on the potential
contribution of rare genomic variation to schizophrenia risk.
Copy number variants (CNVs) are a well-established source
of pleiotropic risk, ranging from asymptomatic carriership to
a complex constellation of symptoms affecting multiple
organ systems, such as the 22q11.2 microdeletion syndrome
[4]. In a large-scale schizophrenia case-control cohort ana-
lysis, known pathogenic CNVs were signiﬁcantly more fre-
quent in cases (2%) than controls (0.4%) [5, 6]. Moreover, an
independent study found that large (>500 kb) CNVs are
enriched in loci associated with schizophrenia by GWAS and
frequently involve genes encoding proteins located in the
postsynaptic density [7].
In addition to microarray-based genotyping methods, the
development of next-generation sequencing has allowed the
possibility to examine whether rare single nucleotide var-
iants or small insertions-deletions contribute to schizo-
phrenia risk. A Swedish cohort including 2536 cases and
2543 controls yielded no single mutation or single gene
reaching genome-wide signiﬁcance for association with
schizophrenia, but conﬁrmed a similar enrichment of gene
sets for synaptic function as previously identiﬁed for genes
located in schizophrenia-associated CNVs and GWAS loci
[8]. Moreover, trio-based studies have identiﬁed a number
of candidate genes through identiﬁcation of recurrent de
novo mutations [9, 10] and an increased burden of muta-
tions occurring in genes encoding glutamatergic post-
synaptic proteins [11].
Recent genetic and induced pluripotent stem cell (iPSC)-
based studies have converged on a model by which neu-
ronal function, and in particular synaptic transmission, is a
major pathophysiological mechanism of schizophrenia [3,
8, 11–13]. However, functional neuronal alterations may
arise either by direct cell-type autonomous changes to
neurons themselves, or indirectly through a primary
pathophysiological inﬂuence on other cell types that inﬂu-
ence neuronal function. Numerous studies have reported the
involvement of glial cell biology in the pathophysiology of
schizophrenia, including alterations in oligodendrocytes,
myelination, and white matter integrity [14–19], which
directly regulate neuronal function.
Abnormalities of the integrity of the white matter are
strongly associated with schizophrenia [20]. The late ado-
lescent critical period for cerebral cortex myelination has
long been recognized as overlapping closely with the typical
age of onset for schizophrenia [16, 17]. Myelination-related
genes have been shown to be enriched for common variants
associated independently to white matter integrity [21] and
schizophrenia [15, 22]. Two recent brain imaging studies
have elegantly compared white matter integrity in 16p11.2
deletion and duplication carriers [23, 24] of which only the
16p11.2 duplication confers increased risk for schizophrenia
[6]. Notably, both global fractional anisotropy (FA) and
white matter volume were selectively decreased in 16p11.2
duplication carriers. However, despite increasing evidence of
an association between schizophrenia and myelination
integrity, the molecular and cellular mechanisms by which
oligodendrocyte lineage dysfunction might inﬂuence schi-
zophrenia risk have remained largely unknown.
We now report genetic and functional evidence of oli-
godendrocyte progenitor cell dysfunction in schizophrenia.
Using a family-based genetic approach, we observed mul-
tiple rare missense mutations in CSPG4 that segregate with
schizophrenia. Functional studies using iPSCs repro-
grammed from affected CSPG4 mutation carriers and their
unaffected non-carrier siblings revealed that patient-derived
OPCs exhibit abnormal post-translational processing, aber-
rant subcellular localization of CSPG4/NG2, abnormal
cellular morphology, reduced cellular viability, and
impaired oligodendrogenesis. Moreover, diffusion tensor
imaging (DTI) of CSPG4 mutation carriers conﬁrmed a
global impairment in white matter integrity, together pro-
viding support for OPC dysfunction as a candidate patho-
physiological mechanism of schizophrenia.
Methods summary
Genetic analysis
Linkage and copy number analysis was performed with
Illumina HumanCytoSNP-12v2 chip arrays using an
affected-only model with an assumption of 99.9% pene-
trance. Analysis revealed a total of 294.34 Mb of genomic
regions, with suggestive linkage on chromosomes 2, 11, 14,
15, and 16. Whole-genome exome sequencing was per-
formed twice: initially at 40×, and again at 90× coverage.
Exome variants were considered for additional validation if
they were rare (minor allele frequency (MAF) < 0.001),
predicted to alter coding sequence (missense, nonsense,
frameshift, essential splice site), and occurred within the
regions of suggestive linkage.
Cellular studies
Human iPSCs were differentiated to neural progenitor cells
(NPCs) and neurons by embryoid body-based neural
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differentiation [25]. Electrophysiology was performed in
whole-cell patch-clamp conﬁguration after 8–10 weeks of
differentiation. iPSC-derived OPCs were differentiated
according to Monaco et al. [26] with modiﬁcations. Bioti-
nylation of cell surface proteins was adapted from Huang
et al. [27]. OPC viability was assessed by quantitative
ﬂuorometric monitoring of resazurin conversion to resoruﬁn
[28]. Myelination assay was performed using ex vivo
organotypic cerebral cortex slices of Shiverer mice, as
previously described [29, 30].
Magnetic resonance imaging (MRI)
Two patients and one control sibling of the discovery family
were subjected to MRI scanning. Population controls (n=
294) matched on age, gender, and pack-years of cigarette
smoking were selected from the Rotterdam Study. MRI
images were obtained using a 1.5 Tesla General Electric
(GE Healthcare, Milwaukee, Wisconsin, USA) MR system
using a bilateral phased-array head coil. A full description
of the imaging protocol and Rotterdam Study design has
been described elsewhere [31]. An in-house MATLAB
(Mathworks, Natick, MA) program was used to quantify the
number and spatial characteristics of white matter “potholes”
along the major white matter tracts [32].
Results
Genetic ﬁndings in the discovery family
A non-consanguineous family of Dutch ancestry was
ascertained with a pattern of schizophrenia inheritance
compatible with autosomal dominant transmission. The
core pedigree consisted of a couple and their nine children
(ﬁve males, four females) of whom the father and four sons
suffered from non-syndromic schizophrenia (Fig. 1a and
Supplementary Table 1).
Genome-wide parametric linkage analysis was per-
formed on peripheral blood DNA using an autosomal-
dominant, affected-only model of inheritance, in order to
identify genomic regions shared among all affected family
members (Supplementary Table 2). Whole exome sequen-
cing was performed on three individuals of the family
(pedigree IDs: II-2, III-5, and III-9; Fig. 1a). Five candidate
heterozygous variants were identiﬁed based on the follow-
ing criteria: (a) located within the genomic regions shared
among all affected family members, (b) predicted to affect
protein coding (missense, nonsense, frameshift, splice site),
(c) called in at least one of the affected individuals (III-5
and III-9), (d) absent from the unaffected mother (II-2), (e)
absent from dbSNP129, and (f) with a MAF< 0.001 in
the Exome Aggregation Consortium (ExAC) browser
(Europeans non-Finnish) [33], EVS6500 European Amer-
icans, NHLBI Exome Sequencing Project (ESP) [34], 1000
Genomes [35], and Genome of the Netherlands (GoNL)
[36] cohorts (Supplementary Table 3). Genotyping of these
variants was performed by Sanger sequencing in all parti-
cipating family members.
Among the ﬁve candidate variants, CSPG4 c.391G>A
(p.A131T) was the only variant shared by all affected
family members and absent in all unaffected relatives,
including in the extended family (Fig. 1a). CSPG4 c.391G
>A (p.A131T) is present in the Exome Aggregation Con-
sortium Browser (Total [forward strand]: T= 6/C=
118,148 alleles [MAF 5.08× 10−5], European (Non-Fin-
nish): T= 5/C= 64,215 alleles [MAF 7.79× 10−5]) [33]
but absent from the Swedish Schizophrenia Exome
Sequencing Study (2536 cases, 2543 controls) [8], 1000
Genomes [35], and GoNL [36].
Additional genotyping of CSPG4 discovery family
variant
In an effort to further characterize the frequency of CSPG4
c.391G >A (p.A131T) in the Netherlands, we performed
TaqMan genotyping and Sanger sequencing validation in an
independent Dutch cohort of 1219 schizophrenia cases and
in the general population-based Rotterdam Study cohort
[37] (10,611 subjects). One carrier was identiﬁed among the
schizophrenia cases (MAFcases 4.1× 10
−4) and three within
the general population (MAFpopulation 1.4× 10
−4). The
patient carrier had a long history of severe psychiatric
illness, including multiple hospital admissions and chronic
antipsychotic and antidepressant medication. Her most
recent prescriptions included penﬂuridol oral depot
(20 mg/week) and venlafaxine (37.5 mg/day). Family
members could not be ascertained for additional psychiatric
history or genotyping. Among the three unrelated carriers
(maximum pairwise π^ ¼ 0:078) identiﬁed in the Rotterdam
Study general population cohort, two had a clinically sig-
niﬁcant history of psychiatric illness (π^ ¼ 0:055). One of
the subjects had a history of multiple inpatient psychiatric
hospitalizations for depression, and the other required
chronic antidepressant and anxiolytic pharmacotherapy.
Notably these ﬁndings were unlikely due to chance alone,
given the 12.76% period prevalence of antidepressant use in
the Rotterdam Study cohort and 0.065% annual prevalence
of inpatient psychiatric hospitalization in the Netherlands
[38, 39] (Binomial P= 8.8× 10−3).
Identiﬁcation of a second rare CSPG4 variant that
segregates with schizophrenia
A previous study identiﬁed suggestive linkage at chromo-
some 15q22-24, containing CSPG4, in a cohort of
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175 families with schizophrenia or schizoaffective disorder
of Central American/Hispanic origin [40, 41]. We therefore
sequenced the full open reading frame of CSPG4 in one
proband from each of the 73 families that positively
contributed to the linkage signal at this locus (markers
D15S131 and D15S655) (Supplementary Table 4). Four rare
missense variants were identiﬁed with MAF< 0.005
(ExAC Browser Latino) (Fig. 1, Supplementary Fig. 1).
However in contrast to the other three variants, CSPG4
c.2702T>G (p.V901G) was found in two independent
families, without evidence of incomplete penetrance (Fig. 1d,
f), and located within a LamG domain similar to the c.391G
>A (p.A131T) discovery family variant (Fig. 1e). Moreover,
the c.2702T>G p.V901G variant was nominally enriched in
cases from the Swedish Schizophrenia Exome Sequencing
Study [8] (MAFcases 2.19× 10
−3; MAFcontrols 5.82× 10
−4,
Fisher’s Exact Test P= 0.026, OR 3.77, 95% CI
1.05–13.52). Together, these ﬁndings suggest that rare
Fig. 1 Familial segregation of
CSPG4 mutations with
schizophrenia. a Pedigree of
multiplex discovery family with
schizophrenia. Symbols: ﬁlled,
schizophrenia; open, unaffected;
G/A, heterozygous carrier of the
CSPG4 c.391G>A mutation
(CSPG4A131T); G/G,
homozygous reference. b
Representative sequencing
results for heterozygous carriers
of the CSPG4 c.391G>A
mutation. The lower panel
reﬂects homozygous reference
sequence. c Homology model of
the ﬁrst Laminin G domain of
CSPG4. Structural alignment of
the reference (green) and mutant
model (magenta) reveals a
difference in the predicted
interaction between amino acid
positions 131 and 96 (Leu) in
the opposing β-strand inside the
hydrophobic core of the β-
sandwich (predicted alterations
of the side chains in red). d
Family pedigrees segregating
the CSPG4 c.2702T>G
mutation (CSPG4V901G).
Symbols: ﬁlled, schizophrenia;
open, unaffected; T/G,
heterozygous carrier of the
CSPG4 c.2702T >G mutation;
T/T, homozygous reference. e
Three-dimensional structural
homology modeling of the
putative 3rd LamG domain of
CSPG4 (a.a. 634–921),
demonstrating the outside
surface location of Val901. f
Representative Sanger
sequencing trace of
heterozygous carrier of the
CSPG4 c.2702T >G mutation
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coding variants of CSPG4might inﬂuence the risk of familial
schizophrenia.
Structural protein modeling of CSPG4 mutations
The CSPG4A131T and CSPG4V901G mutations are located
within the ﬁrst and third Laminin G domain of the protein
encoded by CSPG4, known as neural/glial 2 (NG2) (Fig. 1c,
e). Laminin G (LamG) domains are highly conserved across
a diverse group of extracellular matrix proteins [42]. Intri-
guingly, several schizophrenia-associated genes such as
NRXN1 and LAMA2 also contain LamG domains [10, 43–
45]. Crystal structures of LamG domains in the Protein Data
Bank allowed homology modeling of the LamG domains of
NG2. Models implemented using Phyre2 [46] and
I-TASSER [47] both suggested that in the reference
sequence, Ala131 and Leu96 interact across opposing
β-sheets inside the hydrophobic core of the β-sandwich. The
mutation of Ala131, which has a small hydrophobic side
chain, to Thr131, containing a larger polar side chain, sug-
gests a conformational change impairing the proper folding
of the β-sandwich (Fig. 1c).
Interestingly, CSPG4V901G is located in a putative 3rd
LamG domain predicted by I-TASSER [47] (a.a. 634–921,
Fig. 1e). This region has not previously been annotated as a
LamG domain, despite the striking structural homology to
other LamG domains with available crystal structures, most
notably that of NRXN1 [48–50]. In contrast to the
CSPG4A131T mutation that is located on the inside of the
globular structure of the ﬁrst LamG domain of NG2, the
CSPG4V901G mutation is predicted to be located on the
outside of the putative third LamG domain (Fig. 1e),
therefore perhaps affecting protein–protein interactions.
Intriguingly, the same protein region has been found to bind
to collagen V and VI, implicated in cell adhesion and
migration of NG2-expressing cells [51, 52].
Family-based iPSC modeling of the CSPG4A131T
mutation
No evidence for a cell-autonomous neuronal phenotype
Recent genetic and iPSC-based studies of schizophrenia
have converged on a model by which neuronal function,
and in particular synaptic transmission, is a major patho-
physiological mechanism [3, 8, 11–13]. We obtained skin
biopsies for iPSC reprogramming from three affected
CSPG4A131T carriers and three unaffected non-carriers
within the core sibship of the discovery family (Supple-
mentary Fig. 2a–d). Directed differentiation of iPSCs
yielded forebrain-speciﬁed NPCs uniformly positive for
Nestin, SOX2, Vimentin, and FOXG1 (Supplementary
Fig. 2e).
NPCs were differentiated to neural cultures for
8–10 weeks, which notably lack cells of the oligoden-
drocyte lineage including OPCs. Both control and patient-
derived neurons developed robust synaptic network
connectivity, conﬁrmed by confocal immunoﬂuorescence
(Fig. 2a–c) and whole-cell patch-clamp electrophysiological
recordings (Fig. 2d–r). Overall, neurons derived from
patient carriers and their unaffected siblings had largely
similar electrophysiological properties, including passive
membrane properties, action potential characteristics, and
synaptic physiology. However, two electrophysiological
parameters were signiﬁcantly different between patient and
control iPSC-derived neurons—input resistance (control:
1233± 88.9 mΩ, patient: 1605± 112 mΩ; t50= 2.54, P=
0.01) and AP threshold (control: –51.52± 0.77 mV, patient:
–48.63± 0.67 mV; t49= 2.84, P= 0.007).
Abnormal post-translational processing and subcellular
localization of CSPG4A131T in OPCs
Given the highly abundant expression of NG2 in OPCs,
widely referred to as NG2 cells, we next sought to inves-
tigate the inﬂuence of the CSPG4A131T mutation on iPSC-
derived OPCs. Directed differentiation of iPSCs to OPCs
resulted in robust expression of the lineage-speciﬁc markers
NG2, PDGFRα, Olig2, and SOX10 (Supplementary Fig. 3).
We ﬁrst examined the subcellular distribution of NG2, as
the structural homology modeling of the CSPG4A131T
mutation suggested aberrant protein folding (Fig. 1c). Since
NG2 is a transmembrane protein, it requires processing by
the secretory pathway. Consistent with an impairment of
protein processing, CSPG4A131T patient-derived OPCs
showed a highly abnormal subcellular localization of NG2
exempliﬁed by an increase of co-localization with the
endoplasmic reticulum marker calreticulin (t= 5.08,
P= 0.007) (Fig. 3a, b).
In order to further characterize the alteration of
NG2 subcellular localization, we performed surface bioti-
nylation of CSPG4A131T patient and non-carrier sibling
control OPCs. NG2 is known to undergo extensive post-
translational modiﬁcation [53, 54], including the addition of
chondroitin sulfate moieties at Ser999 [55]. Consequently,
NG2 appears as multiple bands by western blotting: a sharp
band at 300 kDa corresponding to an unmodiﬁed form of
NG2 which lacks chondroitin sulfate side chains, and a
large polydisperse smear at >300 kDa corresponding to
NG2 with chondroitin sulfate modiﬁcation. Pre-incubation
with chondroitinase ABC to enzymatically cleave the
chondroitin sulfate side chains eliminated the >300 kDa
polydisperse smear (modiﬁed NG2) and increased the
300 kDa band (unmodiﬁed NG2) (Supplementary Fig. 4a).
The total level of NG2 protein was similar between
patient and control OPCs in whole-cell lysates (t= 0.51,
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P= 0.62) (Supplementary Figs. 4, 5). However, patient
OPCs exhibited a signiﬁcant decrease in the ratio of mod-
iﬁed vs. unmodiﬁed NG2 compared to control OPCs. This
ﬁnding was observed in whole-cell lysate (t= 2.88,
P= 0.04), as well as independently in the intracellular
(t= 3.50, P= 0.02) and surface protein fractions of OPCs
(t= 3.31, P= 0.03) (Supplementary Fig. 4b, c). Taken
together, these results demonstrate that the CSPG4A131T
mutation results in abnormal processing of NG2 protein.
Abnormal morphology of OPCs derived from CSPG4A131T
mutation carriers
In addition to the abnormal processing of NG2 protein, we
also observed distinct morphological differences between
OPCs derived from patients and controls (Fig. 3c). Patient-
derived OPCs exhibited a size distribution that was strongly
shifted toward smaller cells, a ﬁnding that was highly
signiﬁcant across all patient and control lines
(Kolmogorov–Smirnov D= 0.25, P= 3.0× 10−8; Fig. 3d).
Overall, these results suggest that abnormal processing of
NG2 inﬂuences the function of OPCs derived from
CSPG4A131T mutation carriers.
Patient OPCs have reduced viability and
oligodendrogenesis
Abnormally high co-localization of mutant NG2 with cal-
reticulin is consistent with retention of misfolded mutant
NG2 in the endoplasmic reticulum. The extensive literature
demonstrating impairments of cell viability resulting from
misfolded proteins [56, 57] led us to hypothesize that the
abnormal subcellular distribution of mutant NG2 might
reduce the viability of OPCs. Therefore, we performed a
longitudinal monitoring of cell viability using a quantitative
ﬂuorescence-based indicator based on the conversion of
Fig. 2 Normal passive, active, and synaptic function in CSPG4A131T
patient iPSC-derived neurons. a Immunostaining of iPSC-derived
neural cultures after 8 weeks of differentiation (scale bar= 10 µm). b,
c Immunostaining with MAP2, PSD95, and synapsin antibodies con-
ﬁrmed the presence of synaptic proteins on dendrites of iPSC-derived
neurons 8 weeks post differentiation (scale bar= 2 µm). d–r Electro-
physiological measurements of iPSC-derived neurons. d Representa-
tive voltage responses to hyperpolarizing (range: −20−0 pA, 5 pA
increments) and depolarizing (10 and 20 pA) current steps (left: con-
trol, right: patient). e Resting membrane potential (RMP) (t44= 1.04,
P= 0.30). f Input resistance (t50= 2.54, P= 0.01). g Current–voltage
(I–V) relationship of patient and control cells. h AHP peak (t49= 1.35,
P= 0.18). i Representative traces of spontaneous action potential (AP)
ﬁring (50 s at RMP; top: control, bottom: patient). j AP amplitude (t49
= 0.31, P= 0.76). k Spontaneous ﬁring rate (t19= 0.03, P= 0.98). l
AP half-width (t49= 0.65, P= 0.52). m AP voltage threshold
(t49= 2.84, P= 0.007). n Representative traces of spontaneous post-
synaptic currents (100 s at −90 mV; top: control, bottom: patient). o
sPSC amplitude (t17= 1.94, P= 0.07). p sPSC frequency (t17= 0.65,
P= 0.52). q sPSC rise time (t17= 0.84, P= 0.41). r sPSC decay time
(t17= 0.84, P= 0.41). d–r Unpaired two-tailed t-test. Passive prop-
erties and evoked APs (N= 24 control, N= 28 patient). Spontaneous
APs (N= 11 control, N= 9 patient). Spontaneous postsynaptic cur-
rents (N= 12 control, N= 7 patient). All error bars are +/− standard
errors of the mean (SEM)
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non-ﬂuorescent resazurin to its ﬂuorescent metabolite
resoruﬁn [28]. As evident throughout the entire 13-day time
course of monitoring, OPCs derived from CSPG4A131T
mutation carriers exhibited a signiﬁcant decrease of
cell viability (two-way repeated measures ANOVA,
P= 8.9× 10−7; Fig. 3e).
OPCs are the exclusive precursor of oligodendrocytes
[58]. Given the reduced viability of patient OPCs, we also
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investigated whether their maturation to oligodendrocytes
might also be impacted. Therefore, we performed ex vivo
co-culture of control and patient OPCs with organotypic
slices of cerebral cortex from myelin-deﬁcient Shiverer
mice that carry a homozygous mutation of Mbp. The Shi-
verer myelination assay is a widely implemented method for
assessing the myelination potential of OPCs, using culture
conditions that promote OPCs differentiation to myelinating
oligodendrocytes [30]. Consequently, MBP expression is
entirely attributable to cells differentiated from the trans-
planted human OPCs, since Shiverer mice themselves lack
Mbp. Consistent with their decreased viability, patient
OPCs exhibited an impaired maturation to MBP-expressing
oligodendrocytes (t= 2.17, P= 0.038; Fig. 3f, g).
Transfection of OPCs with mutant isoforms of NG2
To further investigate the causality of the CSPG4A131T and
CSPG4V901G mutations, we transfected either the wild-type
(WT) or mutant isoforms into OPCs derived from healthy
non-carrier siblings. Expression of CSPG4A131T recapitu-
lated the abnormal retention in the endoplasmic reticulum,
similarly as observed in patient OPCs (one-way ANOVA,
WT vs. A131T: P= 5.2× 10−9; Fig. 4a, b). Moreover,
OPCs expressing the CSPG4V901G mutation also exhibited a
signiﬁcantly increased proportion of cells with co-
localization to the endoplasmic reticulum compared to
WT transfected OPCs (WT vs. V901G: P= 7.5× 10−6),
albeit lower than observed for the CSPG4A131T mutation.
Notably, however, expression of the CSPG4V901G mutation
resulted in a distinct accumulation within putative intra-
cellular vesicles that was evident in both OPCs (Fig. 4a,
inset) and U373 glioblastoma cells (Supplementary Fig. 6),
but not observed with expression of the CSPG4A131T
mutation in either of these cell types. At present, although
we have not yet succeeded in identifying the subcellular
compartment to which these CSPG4V901G-expressing intra-
cellular vesicles belong, lysosomes have been excluded
based on the lack of signiﬁcant co-localization with
lysosomal-associated membrane protein 1 (Supplementary
Fig. 6).
Lastly, we sought to evaluate the causality of CSPG4
mutations for mediating the impaired cell viability observed
for patient OPCs. Therefore, we performed transient trans-
fections of either WT or mutant NG2 isoforms into OPCs
derived from healthy non-carrier siblings and assessed cell
survival after 48 h when plasmid expression was maximal.
OPCs transfected with either CSPG4A131T or CSPG4V901G
exhibited a signiﬁcant decrease in survival compared to
CSPG4WT (one-way ANOVA, WT vs. A131T: P= 0.006;
WT vs. V901G: P= 3.4× 10−4; Fig. 4c). Notably, we also
attempted the same experiment with patient OPCs; how-
ever, patient OPCs consistently died following the trans-
fection procedure, regardless of whether the transfection
was performed using WT or mutant NG2, or empty vector,
a ﬁnding that independently conﬁrms their distinct
vulnerability.
Impaired white matter microstructure in CSPG4A131T
mutation carriers
Given the observed abnormalities of patient-derived OPCs,
we reasoned that affected CSPG4A131T mutation carriers
might exhibit impairments of white matter integrity. There-
fore, we performed brain MRI-based DTI in affected carrier
and unaffected non-carrier siblings and compared them with
294 subjects from the general population Rotterdam Study
cohort matched for age, gender, smoking behavior, and
alcohol use (Fig. 5a). DTI images were analyzed for global
and focal reductions in FA, the latter referred to as white
matter potholes [59]. Affected carriers exhibited both a
signiﬁcantly higher number of white matter potholes (P=
2.2× 10−5) and lower global FA (P= 8.2× 10−3), com-
pared to unaffected sibling and matched general population
controls (potholes: 2.95± 3.52, 95% CI 2.55–3.35; global
FA: 0.415± 0.015, 95% CI 0.413–0.417; Fig. 5b, c).
Discussion
Our ﬁndings provide convergent genetic and functional
neurobiological evidence that oligodendrocyte progenitor
cell dysfunction might inﬂuence the pathophysiology of
schizophrenia. We identiﬁed two different rare missense
mutations in CSPG4 exhibiting familial segregation with
schizophrenia. The discovery family CSPG4A131T mutation
Fig. 3 Aberrant NG2 subcellular localization, morphology, and via-
bility of CSPG4A131T patient OPCs. a, b Immunostaining for NG2 and
calreticulin (CALR) reveals increased ER colocalization of NG2 in
patient OPCs (scale bar= 10 µm). Quantiﬁcation was performed in
two independent experiments with three control and three patient OPC
lines each (t = 5.08, P = 0.007). c OPCs derived from mutation
carriers exhibit an abnormally small morphology (scale bars= 10 µm).
d Cumulative distribution of OPC area (µm2; n= 361 control cells, n
= 217 patient cells) demonstrates that OPCs derived from affected
mutation carriers are signiﬁcantly smaller than from their unaffected
non-carrier siblings. Control and patient cell size distributions were
compared by Kolmogorov–Smirnov test (D= 0.25, P= 3.0× 10−8).
Dark lines show group mean± standard error. Gray and pink lines
show the results from each of the individual control and patient sub-
jects, respectively. e Fluorometric cell viability assay of OPCs derived
from affected mutation carriers vs. their unaffected non-carrier siblings
(two-way repeated measures ANOVA, P= 8.9× 10−7). f Repre-
sentative z-stacked images of organotypic cerebral cortex slices of
homozygous shiverer mice transplanted with OPCs derived from
affected mutation carriers or their unaffected non-carrier siblings.
Human nuclear antigen (hNA), green; MBP, red (scale bar= 100 µm).
g MBP surface area normalized to hNA+ cells per slice (t= 2.17,
P= 0.038)
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was associated with abnormal protein processing, OPC
morphology, cellular viability, and oligodendrogenesis. The
second mutation (CSPG4V901G), also located in a LamG
domain, segregated with schizophrenia in two independent
pedigrees and exhibited nominally signiﬁcant enrichment in
the Swedish Schizophrenia Exome Sequencing Study [8].
Moreover, induced expression of CSPG4A131T and
CSPG4V901G isoforms conﬁrmed the likely pathogenicity of
these mutations for OPC function. Importantly, however,
our ﬁndings leave still unaddressed the question of the
extent to which there are distinct vs. shared pathophysio-
logical mechanisms in schizophrenia attributable to com-
mon polygenic risk, CNVs, or other rare familial variants.
Our genetic ﬁndings highlight some of the challenges
frequently encountered in the effort to identify pathogenic rare
variants underlying common diseases such as schizophrenia.
Although we identiﬁed three independent families exhibiting
segregation of two different rare CSPG4 missense variants
with complete penetrance, none of these families was large
enough on its own to achieve a genome-wide signiﬁcant LOD
score. Moreover, although the rare MAF of the CSPG4A131T
mutation precluded case/control validation in the Swedish
Schizophrenia Exome Sequencing Study, two of the three
CSPG4A131T mutation carriers in the general population Rot-
terdam Study cohort had a clinically signiﬁcant history of
psychiatric illness that was unlikely due to chance. Further-
more, the CSPG4V901G mutation was present in the Swedish
cohort with a nominally signiﬁcant enrichment in cases vs.
controls. Additional follow-up studies in larger cohorts will be
required to deﬁnitively evaluate the association between
schizophrenia and rare CSPG4 variants.
Genetic variation in CSPG4 might confer a pleiotropic
risk for mental illness since two of the CSPG4A131T mutation
carriers identiﬁed in the general population Rotterdam
Fig. 4 Transfection of CSPG4A131T and CSPG4V901G mutations in
healthy non-carrier sibling OPCs. Control OPCs were transiently
transfected with plasmids expressing WT or mutant CSPG4 isoforms
fused to EGFP. a Confocal images of transfected cells conﬁrm a
normal extracellular membrane-localization of CSPG4WT-EGFP. In
contrast, a high proportion of OPCs transfected with CSPG4A131T-
EGFP exhibited colocalization with the endoplasmic reticulum marker
calreticulin (CALR), reminiscent to patient OPCs with endogenous
CSPG4A131. OPCs expressing CSPG4V901G-EGFP also revealed an
increased proportion with CALR colocalization, but additionally
demonstrated a distinctly abnormal targeting within putative intracel-
lular vesicles that were negative for CALR (insets) (scale bars: main
panels= 10 μm, insets= 3 μm). b Percentage of transfected OPCs
with colocalization of CSPG4 isoforms with CALR (WT vs. A131T:
t= 10.36, P= 5.2× 10−9; WT vs. V901G: t= 6.20, P= 7.5× 10−6).
c Cell survival at 48 h after transfection of OPCs (WT vs. A131T:
t= 3.11, P= 0.006; WT vs. V901G: t= 4.41, P= 3.4× 10−4)
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Study cohort had a clinically signiﬁcant history of depres-
sion. Interestingly, a mouse model of OPC depletion was
recently shown to exhibit depression-like behavior [60].
Such pleiotropic inﬂuences on mental health outcomes
would be consistent with many of the previously identiﬁed
genetic risk factors for schizophrenia [61, 62]. Furthermore,
originally named as melanoma-associated chondroitin sul-
fate proteoglycan upon its cloning [63], NG2/CSPG4 has
since been widely implicated in a wide variety of human
cancers both as a diagnostic marker and a therapeutic target,
including for glioblastoma and melanoma [64, 65].
The protein sequence surrounding the CSPG4A131T
mutation is conserved only among higher-order primates,
suggesting recent evolutionary pressure. In contrast, the
CSPG4V901G variant is predicted to be a disease-causing
mutation by PolyPhen2 [66]. In non-primate vertebrates, the
reference amino acid at position 131 is threonine,
corresponding to the patient mutation CSPG4A131T and
contributing to a benign PolyPhen score. Interestingly, this
is analogous to the human SNCAA53T mutation, one of the
most well-established mutations for autosomal dominant
Parkinson’s Disease [67]. In mice, the reference amino acid
at SCNA position 53 is a threonine. But notably, although
transgenic expression in mice of the reference human SCNA
sequence is benign, introduction of the human SNCAA53T
mutation is highly pathogenic [67].
To investigate the cellular pathophysiology resulting
from mutation of CSPG4, we derived iPSCs from affected
and unaffected siblings of the discovery family. Detailed
electrophysiological analysis of patient-derived neurons
revealed an increase in input resistance and depolarized
shift in AP threshold. Multiple previous studies have
demonstrated primary functional neuronal mechanisms in
human iPSC models of schizophrenia [3, 8, 11–13, 68];
Fig. 5 White matter abnormalities in CSPG4A131T patients. a White
matter potholes found in the two affected family members are shown
in red and blue, respectively. Purple regions deﬁne a spatial overlap of
potholes in both patients. The z-measures provide coordinates of the
axial plane in MNI-space. b Mean number of potholes comparing the
matched control population to the unaffected and two affected family
members. c Whole-brain white matter FA comparing the matched
general population subjects to unaffected and affected family mem-
bers. Error bars in b and c reﬂect the standard deviation of the matched
general population subjects. The number above each bar reﬂects the
individual z-score compared to the matched general population group
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however, the changes we observed are distinct from those
previously identiﬁed. Therefore, future studies will be
required to determine the extent to which these differences
may have pathophysiological relevance, and potentially
reﬂect an increased burden of common polygenic risk as
recently observed in familial schizophrenia [69].
Importantly, however, our limited ﬁndings in neurons
compared to OPCs cannot be considered to imply that
neuronal dysfunction is not central to the pathophysiology
of schizophrenia. Rather, these data suggest that
although the symptoms of schizophrenia are ultimately
manifest from neuronal dysfunction, the primary patho-
physiological mechanism could be mediated by direct
neuronal impairments and/or indirectly through non-
neuronal cell types including OPCs, depending upon
the nature of the etiological factors driving disease risk in a
given individual.
OPCs receive extensive GABAergic input from sur-
rounding neurons, which regulate their differentiation to
myelinating oligodendrocytes [70–73]. However, it has
remained less well understood whether OPCs directly
modulate neuronal function independent of myelination.
Notably, two recent studies have suggested novel candidate
mechanisms by which OPC dysfunction might directly
regulate neuronal function, including activity-dependent
ecto-domain cleavage of NG2 [54] and local buffering of
extracellular potassium [74].
Regarding the identiﬁed CSPG4 mutations demonstrat-
ing familial segregation with schizophrenia, alterations in
myelination are a parsimonious candidate mechanism given
the convergent ﬁndings of genetic mutations in the OPC
marker protein CSPG4, functional impairments of iPSC-
derived OPCs, and in vivo DTI-based structural brain ima-
ging. Moreover, the abnormal subcellular localization of
NG2 in OPCs expressing the CSPG4A131T or CSPG4V901G
isoforms is consistent with the high susceptibility of cells of
the oligodendrocyte lineage to disruptions in the secretory
pathway, as their maturation requires a substantial upregu-
lation of membrane protein expression [75]. Interestingly,
earlier work has shown a precedent for altered subcellular
localization of NG2, in which mutation of Ser999 results in
an abrogation of chondroitin sulfate side chain modiﬁcation
and altered subcellular localization [55].
Taken together, these ﬁndings are highly consistent with
the growing body of evidence implicating white matter
integrity in schizophrenia neuropathology [59, 76–79].
Indeed, recent ﬁndings demonstrating myelination of
parvalbumin-positive GABAergic interneurons—arguably
the most well-established neuronal cell type implicated in
the pathophysiology of schizophrenia [80, 81]—raises the
intriguing possibility that schizophrenia might result from
neurodevelopmental alterations of PV interneuron myeli-
nation [82].
In summary, our ﬁndings support the validity of family-
based genetics and iPSC modeling to unravel the underlying
mechanisms of complex, heterogeneous psychiatric dis-
eases, and provide evidence in support of oligodendrocyte
precursor cell dysfunction as a novel candidate mechanism
of schizophrenia.
Acknowledgements We wish to thank Roel Ophoff for facilitating the
contribution of the GROUP/Utrecht Study samples and discussions
regarding the genetic analyses, Gerard Borst for discussions regarding
the electrophysiological analyses, and Siska Verploegh for her assis-
tance in sample collection. This project was partially funded by the
Erasmus MC—University Medical Centre Rotterdam, the Netherlands
Organization for Scientiﬁc Research (NWO) and Netherlands Orga-
nisation for Health Research and Development (ZonMW) to SAK,
VB, YE, and JG, the NeuroBasic-PharmaPhenomics consortium to
SAK and YE, Stichting ParkinsonFonds (The Netherlands) to VB,
Netherlands Institute for Regenerative Medicine (NIRM) and Eur-
opean Research Council (Consolidator Grant) to JG. The authors
would like to thank the NHLBI GO Exome Sequencing Project and its
ongoing studies which produced and provided exome variant calls for
comparison: the Lung GO Sequencing Project (HL-102923), the WHI
Sequencing Project (HL-102924), the Broad GO Sequencing Project
(HL-102925), the Seattle GO Sequencing Project (HL-102926), and
the Heart GO Sequencing Project (HL-103010). This study makes use
of data generated by the Genome of the Netherlands Project. A full list
of the investigators is available from www.nlgenome.nl. Funding for
the project was provided by the Netherlands Organization for Scien-
tiﬁc Research under award number 184021007, dated 9 July 2009 and
made available as a Rainbow Project of the Biobanking and Biomo-
lecular Research Infrastructure Netherlands (BBMRI-NL). The
sequencing was carried out in collaboration with the Beijing Institute
for Genomics (BGI). The generation and management of genomics
data for the Rotterdam Study were supported by the Netherlands
Organisation of Scientiﬁc Research Investments (nr. 175.
010.2005.011, 911-03-012) and the Netherlands Genomics Initiative
(NGI) project nr. 050-060-810 (Netherlands Consortium for Healthy
Ageing; NCHA). We thank the members of the Human Genomics
Facility (HuGeF) and the ERGO support team for their help in sam-
pling the data and in creating the database. The Rotterdam Study is
funded by Erasmus Medical Centre and Erasmus University, Rotter-
dam, Netherlands Organisation for Health Research and Development
(ZonMw), the Research Institute for Diseases in the Elderly (RIDE),
the Ministry of Education, Culture and Science, the Ministry for
Health, Welfare and Sports, the European Commission (DG XII), and
the Municipality of Rotterdam. The authors are grateful to the study
participants, the staff from the Rotterdam Study and the participating
general practitioners and pharmacists. NIMH Study 13—data used in
this research report were collected by the International Neuro-Genetics
Association of Spanish America and the United States (INGASU), and
funded by a collaborative NIMH grant (Genetics of Schizophrenia in
Latino Populations) to Dr. Michael Escamilla (University of Texas
Health Science Center at San Antonio) (MH60881) and to Dr. Ricardo
Mendoza (University of California at Los Angeles-Harbor)
(MH60875). Additional principal investigators who participated in
these grants were Dr. Henriette Raventos (University of Costa Rica,
San Jose, Costa Rica), Dr. Alfonso Ontiveros (Instituto de Informacion
de Investigacion en Salud Mental, Monterrey, Mexico), Dr. Humberto
Nicolini (Medical and Family Research Group, Carracci S.C., Mexico
City, Mexico), Dr. Rodrigo Munoz (Family Health Centers of San
Diego, California), and Dr. Alvaro Jerez (Centro Internacional de
Trastornos Afectivos y de la Conducta Adictiva-CITACA, Guate-
mala). Additional investigators from the University of Texas Health
Science Center at San Antonio included Dr. Albana Dassori and Dr.
Evidence for oligodendrocyte progenitor cell dysfunction in schizophrenia
Rolando Medina. Swedish Schizophrenia Exome Sequencing project:
Data obtained from dbGaP at http://www.ncbi.nlm.nih.gov/gap
through dbGaP accession number (20 September 2015, accession
phs000473.v1.p1). Samples used for data analysis were provided by
the Swedish Cohort Collection supported by the NIMH grant
R01MH077139, the Sylvan C. Herman Foundation, the Stanley
Medical Research Institute, and The Swedish Research Council (grants
2009-4959 and 2011-4659). Support for the exome sequencing was
provided by the NIMH Grand Opportunity grant RCMH089905, the
Sylvan C. Herman Foundation, a grant from the Stanley Medical
Research Institute and multiple gifts to the Stanley Center for
Psychiatric Research at the Broad Institute of MIT and Harvard.
The authors would like to thank the Exome Aggregation Consortium
and the groups that provided exome variant data for comparison. A full
list of contributing groups can be found at https://exac.broadinstitute.
org/about.
Compliance with ethical standards
Conﬂict of interest The authors declare that they have no conﬂict of
interest.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet
2016;6736:1–12.
2. Polderman TJC, Benyamin B, de Leeuw CA, Sullivan PF, van
Bochoven A, Visscher PM, et al. Meta-analysis of the heritability
of human traits based on ﬁfty years of twin studies. Nat Genet
2015;47:702–9.
3. Ripke S, Neale BM, Corvin A, Walters JTR, Farh K-H, Holmans
PA, et al. Biological insights from 108 schizophrenia-associated
genetic loci. Nature. 2014;511:421–7.
4. Sullivan PF, Daly MJ, O’Donovan M. Genetic architectures of
psychiatric disorders: the emerging picture and its implications.
Nat Rev Genet. 2012;13:537–51.
5. Rees E, Walters JTR, Georgieva L, Isles AR, Chambert KD,
Richards AL, et al. Analysis of copy number variations at 15
schizophrenia-associated loci. Br J Psychiatry. 2014;204:108–14.
6. Marshall C, Howrigan D, Merico D, Thiruvahindrapuram B, Wu
W, Greer D, et al. A contribution of novel CNVs to schizophrenia
from a genome-wide study of 41,321 subjects. Cold Spring Harb
Labs J. 2016;49:27–35.
7. Szatkiewicz JP, O’Dushlaine C, Chen G, Chambert K, Moran JL,
Neale BM, et al. Copy number variation in schizophrenia in
Sweden. Mol Psychiatry. 2014;19:762–73.
8. Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N,
Roussos P, et al. A polygenic burden of rare disruptive mutations
in schizophrenia. Nature. 2014;506:185–90.
9. Takata A, Ionita-Laza I, Gogos JA, Xu B, Karayiorgou M. De
novo synonymous mutations in regulatory elements contribute to
the genetic etiology of autism and schizophrenia. Neuron.
2016;89:940–7.
10. Xu B, Ionita-Laza I, Roos JL, Boone B, Woodrick S, Sun Y,
et al. De novo gene mutations highlight patterns of genetic and
neural complexity in schizophrenia. Nat Genet. 2012;44:
1365–9.
11. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer
S, Gormley P, et al. De novo mutations in schizophrenia implicate
synaptic networks. Nature. 2014;506:179–84.
12. Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N,
Sangar S, et al. Modelling schizophrenia using human induced
pluripotent stem cells. Nature. 2011;473:221–5.
13. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR,
Kamitaki N, et al. Schizophrenia risk from complex variation of
complement component 4. Nature. 2016;530:177–83.
14. Nave K-A, Ehrenreich H. Myelination and oligodendrocyte
functions in psychiatric diseases. JAMA Psychiatry. 2014;71:
582–4.
15. Goudriaan A, de Leeuw C, Ripke S, Hultman CM, Sklar P, Sul-
livan PF, et al. Speciﬁc glial functions contribute to schizophrenia
susceptibility. Schizophr Bull. 2014;40:925–35.
16. Fields RD. White matter in learning, cognition and psychiatric
disorders. Trends Neurosci. 2008;31:361–70.
17. Paus T, Keshavan M, Giedd JN. Why do many psychiatric dis-
orders emerge during adolescence? Nat Rev Neurosci.
2008;9:947–57.
18. Terwisscha Van Scheltinga AF, Bakker SC, Van Haren NEM,
Derks EM, Buizer-Voskamp JE, Boos HBM, et al. Genetic schi-
zophrenia risk variants jointly modulate total brain and white
matter volume. Biol Psychiatry. 2013;73:525–31.
19. van den Heuvel MP, Sporns O, Collin G, Scheewe T, Mandl
RCW, Cahn W, et al. Abnormal rich club organization and
functional brain dynamics in schizophrenia. JAMA Psychiatry.
2013;70:783–92.
20. Voineskos AN, Lobaugh NJ, Bouix S, Rajji TK, Miranda D,
Kennedy JL, et al. Diffusion tensor tractography ﬁndings in
schizophrenia across the adult lifespan. Brain. 2010;133:
1494–504.
21. Chavarria-Siles I, White T, de Leeuw C, Goudriaan A, Lips E,
Ehrlich S, et al. Myelination-related genes are associated with
decreased white matter integrity in schizophrenia. Eur J Hum
Genet. 2016;24:381–6.
22. Duncan LE, Holmans PA, Lee PH, O’Dushlaine CT, Kirby AW,
Smoller JW, et al. Pathway analyses implicate glial cells in
schizophrenia. PLoS ONE. 2014;9:e89441.
23. Chang YS, Owen JP, Pojman NJ, Thieu T, Bukshpun P, Wakahiro
MLJ, et al. Reciprocal white matter alterations due to 16p11.2
chromosomal deletions versus duplications. Hum Brain Mapp.
2016;37:2833–48.
24. Owen JP, Chang YS, Pojman NJ, Bukshpun P, Wakahiro MLJ,
Marco EJ, et al. Aberrant white matter microstructure in children
with 16p11.2 deletions. J Neurosci. 2014;34:6214–23.
25. Gunhanlar N, Shpak G, van der Kroeg M, Gouty-Colomer LA,
Munshi ST, Lendemeijer B et al. A simpliﬁed protocol for dif-
ferentiation of electrophysiologically mature neuronal networks
from human induced pluripotent stem cells. Mol Psychiatry. 2017;
doi: 10.1038/mp.2017.56.
26. Monaco MCG, Maric D, Bandeian A, Leibovitch E, Yang W,
Major EO. Progenitor-derived oligodendrocyte culture system
from human fetal brain. J Vis Exp. 2012;70:4274.
27. Huang GN, Zeng W, Kim JY, Yuan JP, Han L, Muallem S, et al.
STIM1 carboxyl-terminus activates native SOC, I(crac) and
TRPC1 channels. Nat Cell Biol. 2006;8:1003–10.
F. M. de Vrij et al.
28. Back SA, Khan R, Gan X, Rosenberg PA, Volpe JJ. A new
Alamar Blue viability assay to rapidly quantify oligodendrocyte
death. J Neurosci Methods. 1999;91:47–54.
29. Stoppini L, Buchs PA, Muller D. A simple method for organo-
typic cultures of nervous tissue. J Neurosci Methods.
1991;37:173–82.
30. Najm FJ, Lager AM, Zaremba A, Wyatt K, Caprariello AV,
Factor DC, et al. Transcription factor–mediated reprogramming of
ﬁbroblasts to expandable, myelinogenic oligodendrocyte pro-
genitor cells. Nat Biotechnol. 2013;31:426–33.
31. Ikram MA, van der Lugt A, Niessen WJ, Krestin GP, Koudstaal
PJ, Hofman A, et al. The Rotterdam Scan Study: design and
update up to 2012. Eur J Epidemiol. 2011;26:811–24.
32. White T, Schmidt M, Karatekin C. White matter ‘potholes’ in
early-onset schizophrenia: a new approach to evaluate white
matter microstructure using diffusion tensor imaging. Psychiatry
Res. 2009;174:110–5.
33. Exome Aggregation Consortium, Lek M, Karczewski K, Minikel
E, Samocha K, Banks E, et al. Analysis of protein-coding genetic
variation in 60,706 humans. Cold Spring Harb Labs J.
2015;536:285–91.
34. Exome Variant Server, NHLBI GO Exome Sequencing Project
(ESP), Seattle, WA. 2013. https://evs.gs.washington.edu/EVS/
35. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM,
Gibbs RA, et al. A map of human genome variation from
population-scale sequencing. Nature. 2010;467:1061–73.
36. Consortium TG of the N. Whole-genome sequence variation,
population structure and demographic history of the Dutch
population. Nat Genet. 2014; 46:818–25.
37. Hofman A, Murad SD, Van Duijn CM, Franco OH, Goedegebure
A, Arfan Ikram M, et al. The Rotterdam Study: 2014 objectives
and design update. Eur J Epidemiol. 2013;28:889–926.
38. Dekker J, Peen J, Gardien R, de Jonghe F, Wijdenes W. Urba-
nisation and psychiatric admission rates in The Netherlands. Int J
Soc Psychiatry. 1997;43:235–46.
39. Wierdsma AI, Van Marle PD, Mulder CL. Aantallen en patronen
van inbewaringstellingen en rechterlijke machtigingen in Maas-
tricht, Groningen en Rotterdam: Bijdrage van stedelijke pro-
blematiek aan regionale verschillen in Bopz-maatregelen. Tijdschr
Psychiatr. 2010;52:143–53.
40. Escamilla M, Hare E, Dassori AM, Peralta JM, Ontiveros A,
Nicolini H, et al. A schizophrenia gene locus on chromosome
17q21 in a new set of families of Mexican and Central American
ancestry: evidence from the NIMH genetics of schizophrenia in
latino populations study. Am J Psychiatry. 2009;166:442–9.
41. Vieland VJ, Walters KA, Azaro M, Brzustowicz LM, Lehner T.
The value of regenotyping older linkage data sets with denser
marker panels. Hum Hered. 2014;78:9–16.
42. Timpl R, Tisi D, Talts JF, Andac Z, Sasaki T, Hohenester E.
Structure and function of laminin LG modules. Matrix Biol.
2000;19:309–17.
43. Xu B, Roos JL, Dexheimer P, Boone B, Plummer B, Levy S, et al.
Exome sequencing supports a de novo mutational paradigm for
schizophrenia. Nat Genet. 2011;43:1–6.
44. Rujescu D, Ingason A, Cichon S, Pietiläinen OPH, Barnes MR,
Toulopoulou T, et al. Disruption of the neurexin 1 gene is asso-
ciated with schizophrenia. Hum Mol Genet. 2009;18:988–96.
45. Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M,
et al. Comparative genome hybridization suggests a role for
NRXN1 and APBA2 in schizophrenia. Hum Mol Genet.
2008;17:458–65.
46. Kelley LA, Sternberg MJE. Protein structure prediction on the
web: a case study using the Phyre server. Nat Protoc.
2009;4:363–71.
47. Zhang Y. I-TASSER server for protein 3D structure prediction.
BMC Bioinforma. 2008;9:40.
48. Miller MT, Mileni M, Comoletti D, Stevens RC, Harel M, Taylor
P. The crystal structure of the α-neurexin-1 extracellular region
reveals a hinge point for mediating synaptic adhesion and func-
tion. Structure. 2011;19:767–78.
49. Chen F, Venugopal V, Murray B, Rudenko G. The structure of
neurexin 1α reveals features promoting a role as synaptic orga-
nizer. Structure. 2011;19:779–89.
50. Holm L, Rosenström P. Dali server: conservation mapping in 3D.
Nucleic Acids Res. 2010;38:W545–9.
51. Burg MA, Nishiyama A, Stallcup WB. A central segment of the
NG2 proteoglycan is critical for the ability of glioma cells to bind
and migrate toward type VI collagen. Exp Cell Res.
1997;235:254–64.
52. Tillet E, Gential B, Garrone R, Stallcup WB. NG2 proteoglycan
mediates beta1 integrin-independent cell adhesion and spreading
on collagen VI. J Cell Biochem. 2002;86:726–36.
53. Nishiyama A, Lin XH, Stallcup WB. Generation of truncated
forms of the NG2 proteoglycan by cell surface proteolysis. Mol
Biol Cell. 1995;6:1819–32.
54. Sakry D, Neitz A, Singh J, Frischknecht R, Marongiu D, Binamé
F, et al. Oligodendrocyte precursor cells modulate the neuronal
network by activity-dependent ectodomain cleavage of glial NG2.
PLoS Biol. 2014;12:e1001993.
55. Stallcup WB, Dahlin-Huppe K. Chondroitin sulfate and cyto-
plasmic domain-dependent membrane targeting of the NG2 pro-
teoglycan promotes retraction ﬁber formation and cell
polarization. J Cell Sci. 2001;114:2315–25.
56. Obacz J, Avril T, Le Reste P-J, Urra H, Quillien V, Hetz C, et al.
Endoplasmic reticulum proteostasis in glioblastoma—from
molecular mechanisms to therapeutic perspectives. Sci Signal.
2017;10:eaal2323.
57. Clayton BLL, Popko B. Endoplasmic reticulum stress and the
unfolded protein response in disorders of myelinating glia. Brain
Res. 2016;1648:594–602.
58. Bergles DE, Richardson WD. Oligodendrocyte development and
plasticity. Cold Spring Harb Perspect Biol. 2016;8:a020453.
59. White T, Ehrlich S, Ho B, Manoach DS, Caprihan A, Schulz SC,
et al. Spatial characteristics of white matter abnormalities in
schizophrenia. Schizophr Bull. 2013;39:1077–86.
60. Birey F, Kloc M, Chavali M, Hussein I, Wilson M, Christoffel DJ,
et al. Genetic and stress-induced loss of NG2 glia triggers emer-
gence of depressive-like behaviors through reduced secretion of
FGF2. Neuron. 2015;88:941–56.
61. Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH,
et al. Genetic relationship between ﬁve psychiatric
disorders estimated from genome-wide SNPs. Nat Genet.
2013;45:984–94.
62. O’Donovan MC, Owen MJ. The implications of the shared
genetics of psychiatric disorders. Nat Med. 2016;22:1214–9.
63. Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P,
et al. Molecular cloning of a human melanoma-associated chon-
droitin sulfate proteoglycan. Proc Natl Acad Sci USA.
1996;93:9710–5.
64. Riccardo F, Iussich S, Maniscalco L, Lorda Mayayo S, La Rosa
G, Arigoni M, et al. CSPG4-speciﬁc immunity and survival
prolongation in dogs with oral malignant melanoma immunized
with human CSPG4 DNA. Clin Cancer Res. 2014;20:
3753–62.
65. Geldres C, Savoldo B, Hoyos V, Caruana I, Zhang M, Yvon E,
et al. T lymphocytes redirected against the chondroitin
sulfate proteoglycan-4 control the growth of multiple solid
tumors both in vitro and in vivo. Clin Cancer Res.
2014;20:962–71.
66. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova
A, Bork P, et al. A method and server for predicting damaging
missense mutations. Nat Methods. 2010;7:248–9.
Evidence for oligodendrocyte progenitor cell dysfunction in schizophrenia
67. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, et al.
Human -synuclein-harboring familial Parkinson’s disease-linked
Ala-53 → Thr mutation causes neurodegenerative disease with
-synuclein aggregation in transgenic mice. Proc Natl Acad Sci
USA. 2002;99:8968–73.
68. Wen Z, Nguyen HN, Guo Z, Lalli MA, Wang X, Su Y, et al.
Synaptic dysregulation in a human iPS cell model of mental
disorders. Nature. 2014;515:414–8.
69. Bigdeli TB, Ripke S, Bacanu S-A, Lee SH, Wray NR, Gejman PV,
et al. Genome-wide association study reveals greater polygenic
loading for schizophrenia in cases with a family history of illness.
Am J Med Genet B Neuropsychiatr Genet. 2016;171:276–89.
70. Lin S, Bergles DE. Synaptic signaling between GABAergic
interneurons and oligodendrocyte precursor cells in the hippo-
campus. Nat Neurosci. 2004;7:24–32.
71. Orduz D, Maldonado PP, Balia M, Vélez-Fort M, de Sars V,
Yanagawa Y et al. Interneurons and oligodendrocyte progenitors
form a structured synaptic network in the developing neocortex.
eLife 2015;4:e06953
72. Zonouzi M, Scaﬁdi J, Li P, McEllin B, Edwards J, Dupree JL,
et al. GABAergic regulation of cerebellar NG2 cell development
is altered in perinatal white matter injury. Nat Neurosci.
2015;18:674–82.
73. Balia M, Vélez-Fort M, Passlick S, Schäfer C, Audinat E, Stein-
häuser C, et al. Postnatal down-regulation of the GABAA receptor
γ2 subunit in neocortical NG2 cells accompanies synaptic-to-
extrasynaptic switch in the GABAergic transmission mode. Cereb
Cortex. 2015;25:1114–23.
74. Maldonado PP, Vélez-Fort M, Levavasseur F, Angulo MC.
Oligodendrocyte precursor cells are accurate sensors of
local K+ in mature gray matter. J Neurosci. 2013;33:
2432–42.
75. Lin W, Popko B. Endoplasmic reticulum stress in disorders of
myelinating cells. Nat Neurosci. 2009;12:379–85.
76. Zalesky A, Fornito A, Seal ML, Cocchi L, Westin CF, Bullmore
ET, et al. Disrupted axonal ﬁber connectivity in schizophrenia.
Biol Psychiatry. 2011;69:80–9.
77. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD,
Hof PR, et al. White matter changes in schizophrenia: evidence
for myelin-related dysfunction. Arch Gen Psychiatry. 2003;60:
443–56.
78. Andreasen NC, Nopoulos P, Magnotta V, Pierson R, Ziebell S, Ho
BC. Progressive brain change in schizophrenia: a prospective
longitudinal study of ﬁrst-episode schizophrenia. Biol Psychiatry.
2011;70:672–9.
79. Windrem MS, Osipovitch M, Liu Z, Bates J, Chandler-Militello
D, Zou L, et al. Human iPSC glial mouse chimeras reveal glial
contributions to schizophrenia. Cell Stem Cell. 2017;21:195–208.
80. Gonzalez-Burgos G, Cho RY, Lewis DA. Alterations in cortical
network oscillations and parvalbumin neurons in schizophrenia.
Biol Psychiatry. 2015;77:1031–40.
81. Marín O. Developmental timing and critical windows for the
treatment of psychiatric disorders. Nat Med. 2016;22:1229–38.
82. Stedehouder J, Kushner SA. Myelination of parvalbumin inter-
neurons: a parsimonious locus of pathophysiological convergence
in schizophrenia. Mol Psychiatry. 2017;22:4–12.
Afﬁliations
Femke M. de Vrij1 ● Christian G. Bouwkamp1,2 ● Nilhan Gunhanlar1 ● Guy Shpak1 ● Bas Lendemeijer1 ●
Maarouf Baghdadi1 ● Shreekara Gopalakrishna 1 ● Mehrnaz Ghazvini3 ● Tracy M. Li3 ● Marialuisa Quadri2 ●
Simone Olgiati2 ● Guido J. Breedveld2 ● Michiel Coesmans1,4 ● Edwin Mientjes5,6 ● Ton de Wit2 ● Frans W. Verheijen2 ●
H. Berna Beverloo2 ● Dan Cohen7 ● Rob M. Kok8 ● P. Roberto Bakker9,10 ● Aviva Nijburg8 ● Annet T. Spijker8 ●
P.M. Judith Haffmans11 ● Erik Hoencamp8,12 ● Veerle Bergink1 ● GROUP Study Consortium ●
Jacob A. Vorstman13,14,15 ● Timothy Wu16 ● Loes M. Olde Loohuis 16 ● Najaf Amin17 ● Carolyn D. Langen18,19,20 ●
Albert Hofman17 ● Witte J. Hoogendijk1 ● Cornelia M. van Duijn17 ● M. Arfan Ikram 17,18,21 ● Meike W. Vernooij17,18 ●
Henning Tiemeier 1,17,19 ● André G. Uitterlinden17,22 ● Ype Elgersma 5,6 ● Ben Distel23 ● Joost Gribnau3 ●
Tonya White19 ● Vincenzo Bonifati2 ● Steven A. Kushner 1
1 Department of Psychiatry, Erasmus Medical Center,
Rotterdam, The Netherlands
2 Department of Clinical Genetics, Erasmus Medical Center,
Rotterdam, The Netherlands
3 Department of Developmental Biology, and Erasmus MC iPS
Facility, Erasmus Medical Center, Rotterdam, The Netherlands
4 Delta Psychiatric Center, Poortugaal, The Netherlands
5 Department of Neuroscience, Erasmus Medical Center,
Rotterdam, The Netherlands
6 ENCORE Expertise Center for Neurodevelopmental Disorders,
Erasmus Medical Center, Rotterdam, The Netherlands
7 Mental Health Care Organization North-Holland North,
Heerhugowaard, The Netherlands
8 Parnassia Psychiatric Institute, The Hague, The Netherlands
9 Department of Psychiatry and Psychology, School of Mental
Health and Neuroscience, Maastricht University Medical Center,
Maastricht, The Netherlands
10 Psychiatric Center GGZ Centraal, Amersfoort, The Netherlands
11 Faculty of Social and Behavioral Sciences Clinical, Health and
Neuro Psychology, Department of Affective Disorders, PsyQ,
Leiden University, Leiden, The Netherlands
12 Institute of Psychology, Leiden University, Leiden, The
Netherlands
13 Department of Psychiatry, Brain Center Rudolf Magnus,
University Medical Center Utrecht, Utrecht, The Netherlands
14 Department of Psychiatry, The Hospital for Sick Children and
University of Toronto, Toronto, Ontario, Canada
15 Program in Genetics and Genome Biology, Research Institute, The
Hospital for Sick Children, Toronto, Ontario, Canada
F. M. de Vrij et al.
16 Center for Neurobehavioral Genetics, Semel Institute for
Neuroscience and Human Behavior, University of California,
Los Angeles, CA, USA
17 Department of Epidemiology, Erasmus Medical Center,
Rotterdam, The Netherlands
18 Department of Radiology, Erasmus Medical Center,
Rotterdam, The Netherlands
19 Department of Medical Informatics, Erasmus Medical Center,
Rotterdam, The Netherlands
20 Biomedical Imaging Group Rotterdam, Departments of Radiology
& Medical Informatics, Erasmus Medical Center, Rotterdam, The
Netherlands
21 Department of Neurology, Erasmus Medical Center,
Rotterdam, The Netherlands
22 Department of Internal Medicine, Erasmus Medical Center,
Rotterdam, The Netherlands
23 Department of Medical Biochemistry, Academic Medical Centre,
Amsterdam, The Netherlands
Evidence for oligodendrocyte progenitor cell dysfunction in schizophrenia
